Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them.
Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total
of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week
for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had
a complete response and 70 patients had a partial response to rituximab. The median duration
of response was 11.2 months.